Spots Global Cancer Trial Database for mdv3100
Every month we try and update this database with for mdv3100 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | NCT02960022 | Prostate Cancer | enzalutamide abiraterone ace... prednisone | 18 Years - | Astellas Pharma Inc | |
| Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients | NCT01902251 | Prostate Cancer Pharmacokinetic... | Enzalutamide ta... Enzalutamide ca... | 18 Years - | Astellas Pharma Inc | |
| A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100 | NCT01534052 | Castration-Resi... | Enzalutamide | 18 Years - | Astellas Pharma Inc | |
| A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | NCT02960022 | Prostate Cancer | enzalutamide abiraterone ace... prednisone | 18 Years - | Astellas Pharma Inc | |
| A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy | NCT02124668 | Castration-Resi... Prostate Cancer | Enzalutamide | - | Astellas Pharma Inc | |
| A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer | NCT01288911 | Prostatic Neopl... | enzalutamide bicalutamide | 18 Years - | Astellas Pharma Inc | |
| Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer | NCT01565928 | Prostate Cancer | MDV3100 | 18 Years - | Pfizer | |
| A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden | NCT03328364 | Metastatic Cast... | enzalutamide docetaxel | 18 Years - | Astellas Pharma Inc | |
| A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | NCT02960022 | Prostate Cancer | enzalutamide abiraterone ace... prednisone | 18 Years - | Astellas Pharma Inc | |
| A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients | NCT01284920 | Prostate Cancer Prostate Neopla... Castration Resi... | MDV3100 | 20 Years - | Astellas Pharma Inc | |
| Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy | NCT01606982 | Metastatic Cast... | MDV3100 | - | Astellas Pharma Inc | |
| A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer | NCT01663415 | Metastatic Cast... | Enzalutamide | - | Astellas Pharma Inc | |
| A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients | NCT01284920 | Prostate Cancer Prostate Neopla... Castration Resi... | MDV3100 | 20 Years - | Astellas Pharma Inc | |
| A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer | NCT02116582 | Metastatic Cast... | Enzalutamide | 18 Years - | Astellas Pharma Inc | |
| A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients | NCT01650194 | Metastatic Cast... | enzalutamide abiraterone ace... prednisone | - | Astellas Pharma Inc | |
| A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide | NCT01977651 | Metastatic Cast... | Enzalutamide | - | Astellas Pharma Inc | |
| A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma | NCT04086758 | Gastric or Gast... | zolbetuximab | 18 Years - | Astellas Pharma Inc | |
| A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer | NCT00510718 | Prostate Cancer Hormone Refract... | MDV3100 | - | Pfizer | |
| An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | NCT04076059 | Metastatic Horm... | Enzalutamide Placebo Androgen depriv... | 18 Years - | Astellas Pharma Inc | |
| Long-Term Specified Drug Use-Results Survey for Xtandi Capsule | NCT02669771 | Castration-resi... | enzalutamide | - | Astellas Pharma Inc | |
| A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy | NCT03641560 | Metastatic Cast... | Enzalutamide Androgen depriv... | 18 Years - | Astellas Pharma Inc | |
| Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer | NCT01597193 | Breast Cancer | enzalutamide anastrozole exemestane fulvestrant enzalutamide exemestane | 18 Years - | Pfizer | |
| A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden | NCT03328364 | Metastatic Cast... | enzalutamide docetaxel | 18 Years - | Astellas Pharma Inc | |
| A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer | NCT01288911 | Prostatic Neopl... | enzalutamide bicalutamide | 18 Years - | Astellas Pharma Inc | |
| Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates | NCT01911728 | Pharmacokinetic... Castration Resi... | MDV3100 Pioglitazone Warfarin Omeprazole Midazolam | 18 Years - | Astellas Pharma Inc | |
| Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer | NCT01565928 | Prostate Cancer | MDV3100 | 18 Years - | Pfizer | |
| A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma | NCT02528643 | Advanced Hepato... | Enzalutamide Placebo | 18 Years - | Astellas Pharma Inc | |
| Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer | NCT01664923 | Prostate Cancer | Enzalutamide Bicalutamide | 18 Years - | Pfizer | |
| An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | NCT04076059 | Metastatic Horm... | Enzalutamide Placebo Androgen depriv... | 18 Years - | Astellas Pharma Inc | |
| Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer | NCT01664923 | Prostate Cancer | Enzalutamide Bicalutamide | 18 Years - | Pfizer | |
| Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide | NCT01946165 | Prostate Cancer | Abiraterone Ace... Prednisone Enzalutamide LHRHa | 18 Years - | M.D. Anderson Cancer Center | |
| A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma | NCT04086758 | Gastric or Gast... | zolbetuximab | 18 Years - | Astellas Pharma Inc |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
